Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06691243
PHASE2

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

Sponsor: University of Maryland, Baltimore

View on ClinicalTrials.gov

Summary

The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo. Participants will: * Visit the clinic once a week for semaglutide or placebo injections * Visit the clinic once every two weeks for labwork, assessments and/or surveys * If consented to optional MRI's, complete two MRI's

Official title: Evaluation Of Semaglutide Safety and Tolerability in Adults With Cocaine Use Disorder With and Without HIV

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-08-07

Completion Date

2027-03

Last Updated

2025-08-24

Healthy Volunteers

No

Interventions

DRUG

Semaglutide

The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.

DRUG

Placebo

Patients randomized to placebo arm will receive placebo injection every week.

Locations (2)

Institute of Human Virology at the University of Maryland School of Medicine

Washington D.C., District of Columbia, United States

Institute of Human Virology at the University of Maryland School of Medicine

Baltimore, Maryland, United States